The OPEN Study

The OPEN Study aims to improve the treatment of nephrotic syndrome (NS) in children by determining the optimal steroid dose for managing relapses.

Nephrotic syndrome (NS) affects around 1 in 50,000 children. Our goal is to explore whether lower doses can be as effective as the traditional high-dose therapy, reducing the severity of side effects like behavioural changes, sleep disruption, and growth issues.

By conducting a rigorous, computer-randomised trial across multiple hospitals, we hope to offer better outcomes for children with NS, ensuring they receive the most effective care with fewer risks.

Treatment for Nephrotic Syndrome (NS)

The standard treatment for NS is steroid therapy. While most children improve with steroids, many experience relapses that can continue for years. Steroids are effective in treating relapses but often come with side effects such as behavioural changes, sleep disturbances, and impacts on appetite, weight, and growth.

Exploring Lower Steroid Doses

Traditionally, high doses of steroids have been used based on international guidelines set many years ago. Recent research suggests that smaller doses may be just as effective, potentially reducing the severity of side effects. However, it is unclear whether lower doses will work for all children or impact the frequency of relapses.

Funding and recruitment

The trial, funded by the Australian Government’s Medical Research Future Fund (MRFF), involves clinicians from eight hospitals across Australia and New Zealand. Recruitment is expected to begin in early 2025 and continue through 2026.

Principal investigator

Professor Jonathan Craig, Vice President and Executive Dean & Matthew Flinders Distinguished Professor. College of Medicine and Public Health, Flinders University